The US FDA approved Janssen R&D LLC’s antidepressant Spravato (esketamine) March 5 with an enhanced Risk Evaluation and Mitigation Strategy (REMS) but also a postmarketing commitment for a monotherapy study that the agency itself has suggested would be difficult to conduct.
Esketamine nasal spray is indicated for use in conjunction with an oral antidepressant for treatment-resistant depression in adults. The FDA...






